ATE491724T1 - Antiangiogene peptide - Google Patents

Antiangiogene peptide

Info

Publication number
ATE491724T1
ATE491724T1 AT05774139T AT05774139T ATE491724T1 AT E491724 T1 ATE491724 T1 AT E491724T1 AT 05774139 T AT05774139 T AT 05774139T AT 05774139 T AT05774139 T AT 05774139T AT E491724 T1 ATE491724 T1 AT E491724T1
Authority
AT
Austria
Prior art keywords
amino acid
acid residue
ile
leu
val
Prior art date
Application number
AT05774139T
Other languages
English (en)
Inventor
Joseph Martial
Ingrid Struman
Ngoc-Quynh-Nhu Nguyen
Robert Brasseur
Laurence Lins
Original Assignee
Univ Liege
Faculte Univ Sciences Agronomiques Gembloux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Liege, Faculte Univ Sciences Agronomiques Gembloux filed Critical Univ Liege
Application granted granted Critical
Publication of ATE491724T1 publication Critical patent/ATE491724T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57518—Placental lactogen; Chorionic somatomammotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57554—Prolactin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
AT05774139T 2004-08-16 2005-08-11 Antiangiogene peptide ATE491724T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04103920A EP1640382A1 (de) 2004-08-16 2004-08-16 Anti-angiogene Peptide
PCT/EP2005/053952 WO2006018418A2 (en) 2004-08-16 2005-08-11 Antiangiogenic peptides

Publications (1)

Publication Number Publication Date
ATE491724T1 true ATE491724T1 (de) 2011-01-15

Family

ID=34929447

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05774139T ATE491724T1 (de) 2004-08-16 2005-08-11 Antiangiogene peptide

Country Status (6)

Country Link
US (1) US7655626B2 (de)
EP (2) EP1640382A1 (de)
JP (1) JP2008509968A (de)
AT (1) ATE491724T1 (de)
DE (1) DE602005025362D1 (de)
WO (1) WO2006018418A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1640382A1 (de) 2004-08-16 2006-03-29 Université de Liège Anti-angiogene Peptide
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
EP2356998A1 (de) 2010-02-17 2011-08-17 Université de Liège Pharmazeutische Zusammensetzung zur Behandlung von thrombosebedingten Krankheiten mit einem Fragment des Proteins der Prolactin-Wachsotumshormon-Plazentalaktogen-Familie
MX2019013819A (es) 2019-11-20 2021-05-21 Univ Mexico Nac Autonoma Oligopeptidos inhibitorios de la angiogenesis y de la funcion vascular.
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) * 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
EP1173191A4 (de) * 1997-05-13 2004-12-01 Univ California Neuartige antiangiogenese peptidagenzien sowie ihre therapeutische und diagnostische verwendung
US6211149B1 (en) * 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
AU4982200A (en) * 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
GB9930160D0 (en) * 1999-12-22 2000-02-09 Biovector Solutions Limited Drug delivery
ITMI20010394A1 (it) * 2001-02-27 2002-08-27 Univ Degli Studi Milano Peptidi ad attivita' antiangiogenica
HUP0402334A3 (en) * 2001-09-04 2007-03-28 Merck Patent Gmbh Modified human growth hormone
WO2004002415A2 (en) * 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
AU2003246614A1 (en) * 2002-06-28 2004-01-19 Faculte Universitaire Des Sciences Agronomiques De Gembloux Novel use of lipopeptide preparations
EP1378515A1 (de) * 2002-07-01 2004-01-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts In Tumorzellen Apoptosis induzierende Peptide
JP2006508072A (ja) * 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用
EP1640382A1 (de) 2004-08-16 2006-03-29 Université de Liège Anti-angiogene Peptide

Also Published As

Publication number Publication date
WO2006018418A3 (en) 2006-08-10
EP1778724B8 (de) 2011-01-26
DE602005025362D1 (de) 2011-01-27
EP1778724B9 (de) 2011-07-20
US20080039384A1 (en) 2008-02-14
EP1778724A2 (de) 2007-05-02
WO2006018418A2 (en) 2006-02-23
JP2008509968A (ja) 2008-04-03
US7655626B2 (en) 2010-02-02
EP1640382A1 (de) 2006-03-29
EP1778724B1 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
ATE477020T1 (de) Prevention und verringerung von ischemia
AR096162A1 (es) Péptidos terapéuticos
MX9606536A (es) Proteinas n-terminalmente extendidas expresadas en levaduras.
ATE152129T1 (de) Inhibitorvarianten der menschlichen protease vom kunitz-typ
ES2104121T3 (es) Variante de un inhibidor de proteasas, de tipo kunitz, de origen humano.
NZ596787A (en) Growth hormone polypeptides and methods of making and using same
ATE517119T1 (de) Einzelketteninsulin
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
ATE366317T1 (de) Herstellung von peptiden und proteinen durch anhäufung in vom endoplasmatischen reticulum abgeleiteten proteinkörpern
DE602005025362D1 (de) Antiangiogene peptide
WO2005123771A3 (en) Oligomeric peptides and their use for the treatment of hiv infections
MX2021014497A (es) Peptidos.
WO2005123771B1 (en) Oligomeric peptides and their use for the treatment of hiv infections
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
DE60003860D1 (de) Peptide, die anti-Zellanhaftungsaktivität aufweisen
RU99116976A (ru) Миелопептиды и их терапевтическое использование
SG170092A1 (en) Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
DK1572725T3 (da) Chi-conotoksinpeptider med en N-terminal pyroglutaminsyre
EP4414384A3 (de) Rekombinantes protein
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
WO2004056871A3 (en) Peptides and their use for the treatment of hiv infections
WO2003022867A3 (en) Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination against sag
ATE482973T1 (de) Peptidfragment von lyve-1 und gegen dieses gerichteter antikörper
AU2003260306A1 (en) Bicyclic oligopeptides
CY1115911T1 (el) Τροποποιημενα πολυπεπτιδια περιοχης kunitz και η χρηση τους στην μειωση της ισχαιμιας ή της εκκινησης μιας συστημικης φλεγμονωδους ανταποκρισης που σχετιζεται με μια χειρουργικη επεμβαση

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties